ARTICLE | Finance
In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M
By Paul Bonanos, Director of Biopharma Intelligence
November 1, 2024 9:26 PM UTC
Two more reverse mergers proposed this week will set up spinouts from Fairmount’s Paragon incubator to become NASDAQ-traded companies, bringing the total to five public companies emerging from the organization.
Fairmount is also co-leading syndicates pouring a total of $500 million into Jade Biosciences Inc. and Crescent Biopharma Inc. as they merge with Aerovate Therapeutics Inc. (NASDAQ:AVTE) and GlycoMimetics Inc. (NASDAQ:GLYC), respectively. Assuming both deals are completed, Paragon will have brought five companies to NASDAQ since mid-2023, including four via reverse merger…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654050/how-fairmount-s-paragon-incubator-steered-two-more-companies-to-nasdaq